BACKGROUND: Onchocerciasis can be effectively controlled as a public health problem by annual mass drug administration of ivermectin, but it was not known if ivermectin treatment in the long term would be able to achieve elimination of onchocerciasis infection and interruption of transmission in endemic areas in Africa. A recent study in Mali and Senegal has provided the first evidence of elimination after 15-17 years of treatment. Following this finding, the African Programme for Onchocerciasis Control (APOC) has started a systematic evaluation of the long-term impact of ivermectin treatment projects and the feasibility of elimination in APOC supported countries. This paper reports the first results for two onchocerciasis foci in Kaduna, Nigeria. METHODS: In 2008, an epidemiological evaluation using skin snip parasitological diagnostic method was carried out in two onchocerciasis foci, in Birnin Gwari Local Government Area (LGA), and in the Kauru and Lere LGAs of Kaduna State, Nigeria. The survey was undertaken in 26 villages and examined 3,703 people above the age of one year. The result was compared with the baseline survey undertaken in 1987. RESULTS: The communities had received 15 to 17 years of ivermectin treatment with more than 75% reported coverage. For each surveyed community, comparable baseline data were available. Before treatment, the community prevalence of O. volvulus microfilaria in the skin ranged from 23.1% to 84.9%, with a median prevalence of 52.0%. After 15 to 17 years of treatment, the prevalence had fallen to 0% in all communities and all 3,703 examined individuals were skin snip negative. CONCLUSIONS: The results of the surveys confirm the finding in Senegal and Mali that ivermectin treatment alone can eliminate onchocerciasis infection and probably disease transmission in endemic foci in Africa. It is the first of such evidence for the APOC operational area.
BACKGROUND:Onchocerciasis can be effectively controlled as a public health problem by annual mass drug administration of ivermectin, but it was not known if ivermectin treatment in the long term would be able to achieve elimination of onchocerciasis infection and interruption of transmission in endemic areas in Africa. A recent study in Mali and Senegal has provided the first evidence of elimination after 15-17 years of treatment. Following this finding, the African Programme for Onchocerciasis Control (APOC) has started a systematic evaluation of the long-term impact of ivermectin treatment projects and the feasibility of elimination in APOC supported countries. This paper reports the first results for two onchocerciasis foci in Kaduna, Nigeria. METHODS: In 2008, an epidemiological evaluation using skin snip parasitological diagnostic method was carried out in two onchocerciasis foci, in Birnin Gwari Local Government Area (LGA), and in the Kauru and Lere LGAs of Kaduna State, Nigeria. The survey was undertaken in 26 villages and examined 3,703 people above the age of one year. The result was compared with the baseline survey undertaken in 1987. RESULTS: The communities had received 15 to 17 years of ivermectin treatment with more than 75% reported coverage. For each surveyed community, comparable baseline data were available. Before treatment, the community prevalence of O. volvulus microfilaria in the skin ranged from 23.1% to 84.9%, with a median prevalence of 52.0%. After 15 to 17 years of treatment, the prevalence had fallen to 0% in all communities and all 3,703 examined individuals were skin snip negative. CONCLUSIONS: The results of the surveys confirm the finding in Senegal and Mali that ivermectin treatment alone can eliminate onchocerciasis infection and probably disease transmission in endemic foci in Africa. It is the first of such evidence for the APOC operational area.
Authors: G De Sole; J Remme; K Awadzi; S Accorsi; E S Alley; O Ba; K Y Dadzie; J Giese; M Karam; F M Keita Journal: Bull World Health Organ Date: 1989 Impact factor: 9.408
Authors: Eddie W Cupp; Brian O Duke; Charles D Mackenzie; Jose Rumbea Guzmán; Juan Carlos Vieira; Jorge Mendez-Galvan; Julio Castro; Frank Richards; Mauricio Sauerbrey; Alfredo Dominguez; Rob R Eversole; Mary S Cupp Journal: Am J Trop Med Hyg Date: 2004-11 Impact factor: 2.345
Authors: A Abiose; I Murdoch; O Babalola; S Cousens; I Liman; J Onyema; J Evans; W Gregory; B Jones Journal: Br J Ophthalmol Date: 1994-01 Impact factor: 4.638
Authors: David Oguttu; Edson Byamukama; Charles R Katholi; Peace Habomugisha; Christine Nahabwe; Monica Ngabirano; Hassan K Hassan; Thomson Lakwo; Moses Katabarwa; Frank O Richards; Thomas R Unnasch Journal: Am J Trop Med Hyg Date: 2013-12-16 Impact factor: 2.345
Authors: Tarig B Higazi; Isam M A Zarroug; Hanan A Mohamed; Wigdan A Elmubark; Tong Chor M Deran; Nabil Aziz; Moses Katabarwa; Hassan K Hassan; Thomas R Unnasch; Charles D Mackenzie; Frank Richards; Kamal Hashim Journal: Am J Trop Med Hyg Date: 2013-05-20 Impact factor: 2.345
Authors: Heather N Paulin; Andreas Nshala; Akili Kalinga; Upendo Mwingira; Ryan Wiegand; Vitaliano Cama; Paul T Cantey Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Joanne P Webster; David H Molyneux; Peter J Hotez; Alan Fenwick Journal: Philos Trans R Soc Lond B Biol Sci Date: 2014-05-12 Impact factor: 6.237
Authors: Wilma A Stolk; David J Blok; Jonathan I D Hamley; Paul T Cantey; Sake J de Vlas; Martin Walker; María-Gloria Basáñez Journal: Clin Infect Dis Date: 2021-06-14 Impact factor: 9.079
Authors: Hugo C Turner; Thomas S Churcher; Martin Walker; Mike Y Osei-Atweneboana; Roger K Prichard; María-Gloria Basáñez Journal: PLoS Negl Trop Dis Date: 2013-04-25